Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Annapurna Poduri, M.D.

Co-Author

This page shows the publications co-authored by Annapurna Poduri and Heather Olson.
Connection Strength

5.357
  1. Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder. J Neurodev Disord. 2021 09 16; 13(1):40.
    View in: PubMed
    Score: 0.987
  2. Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppression. Ann Neurol. 2017 Mar; 81(3):419-429.
    View in: PubMed
    Score: 0.718
  3. Mutations in epilepsy and intellectual disability genes in patients with features of Rett syndrome. . 2015 Sep; 167A(9):2017-25.
    View in: PubMed
    Score: 0.633
  4. Copy number variation plays an important role in clinical epilepsy. Ann Neurol. 2014 Jun; 75(6):943-58.
    View in: PubMed
    Score: 0.597
  5. Early diagnosis and experimental treatment with fenfluramine via the Investigational New Drug mechanism in a boy with Dravet syndrome and recurrent status epilepticus. Epileptic Disord. 2021 Oct 19.
    View in: PubMed
    Score: 0.248
  6. Cerebral visual impairment in CDKL5 deficiency disorder: vision as an outcome measure. Dev Med Child Neurol. 2021 Nov; 63(11):1308-1315.
    View in: PubMed
    Score: 0.241
  7. Genetic diagnoses in epilepsy: The impact of dynamic exome analysis in a pediatric cohort. Epilepsia. 2020 02; 61(2):249-258.
    View in: PubMed
    Score: 0.220
  8. Spectrum of neurodevelopmental disease associated with the GNAO1 guanosine triphosphate-binding region. Epilepsia. 2019 03; 60(3):406-418.
    View in: PubMed
    Score: 0.205
  9. A Recurrent De Novo PACS2 Heterozygous Missense Variant Causes Neonatal-Onset Developmental Epileptic Encephalopathy, Facial Dysmorphism, and Cerebellar Dysgenesis. Am J Hum Genet. 2018 10 04; 103(4):631.
    View in: PubMed
    Score: 0.201
  10. A Recurrent De Novo PACS2 Heterozygous Missense Variant Causes Neonatal-Onset Developmental Epileptic Encephalopathy, Facial Dysmorphism, and Cerebellar Dysgenesis. Am J Hum Genet. 2018 05 03; 102(5):995-1007.
    View in: PubMed
    Score: 0.194
  11. A Model Program for Translational Medicine in Epilepsy Genetics. J Child Neurol. 2017 03; 32(4):429-436.
    View in: PubMed
    Score: 0.178
  12. Genetic forms of epilepsies and other paroxysmal disorders. Semin Neurol. 2014 Jul; 34(3):266-79.
    View in: PubMed
    Score: 0.152
  13. Clinical application and evaluation of the Bien diagnostic criteria for Rasmussen encephalitis. Epilepsia. 2013 Oct; 54(10):1753-60.
    View in: PubMed
    Score: 0.141
  14. Micro-duplications of 1q32.1 associated with neurodevelopmental delay. Eur J Med Genet. 2012 Feb; 55(2):145-50.
    View in: PubMed
    Score: 0.126
  15. Rufinamide for the treatment of epileptic spasms. Epilepsy Behav. 2011 Feb; 20(2):344-8.
    View in: PubMed
    Score: 0.118
  16. Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications. Brain. 2021 Aug 25.
    View in: PubMed
    Score: 0.061
  17. Characterization of the GABRB2-Associated Neurodevelopmental Disorders. Ann Neurol. 2021 03; 89(3):573-586.
    View in: PubMed
    Score: 0.059
  18. Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice. Brain. 2020 07 01; 143(7):2039-2057.
    View in: PubMed
    Score: 0.057
  19. Biological concepts in human sodium channel epilepsies and their relevance in clinical practice. Epilepsia. 2020 03; 61(3):387-399.
    View in: PubMed
    Score: 0.055
  20. A randomized controlled trial of levodopa in patients with Angelman syndrome. Am J Med Genet A. 2018 05; 176(5):1099-1107.
    View in: PubMed
    Score: 0.047
  21. SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures. Neurology. 2015 Sep 15; 85(11):958-66.
    View in: PubMed
    Score: 0.040
  22. The genetics of the epilepsies. Curr Neurol Neurosci Rep. 2015 Jul; 15(7):39.
    View in: PubMed
    Score: 0.040
  23. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia. 2014 Aug; 55(8):1235-44.
    View in: PubMed
    Score: 0.038
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.